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Abstract
Background: The purpose of this study was to examine whether prior outpatient antibiotic use
is associated with increased 30-day mortality, after adjusting for potential confounders, for those
subsequently hospitalized with pneumonia.
Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible
subjects were admitted with a diagnosis of, and had a chest x-ray consistent with, community-
acquired pneumonia. Our primary analysis was a multivariable logistic regression with the
dependent variable of 30-day mortality.
Results: Data was abstracted on 733 subjects at the two hospitals. Mortality was 8.1% at 30-days.
At presentation, 55% of subjects were low risk, 33% were moderate risk, and 12% were high risk.
In our cohort 17% (n = 128) of subjects received antibiotics within 30-days of presentation.
Unadjusted mortality for those who had received prior antibiotics was 7.0% vs. 8.3% for those who
had not (p = 0.6). In the multivariable analysis prior use of antibiotics (odds ratio 0.98, 95%
confidence interval 0.5–2.1) was not significantly associated with 30-day mortality.
Conclusion: Receipt of prior outpatient antibiotics is not significantly associated with 30-day
mortality for patients hospitalized with pneumonia. Our study supports current efforts to increase
the number of patients with pneumonia who are treated as outpatients.
Background
Pneumonia, along with influenza, is the seventh leading
cause of death and the leading cause of infectious death in
the United States [1]. Although mortality due to pneumo-
nia decreased significantly with the introduction of antibi-
otics in the 1950s, since that time mortality has been
stable or increasing [2]. Recently substantial attention has
been focused on increasing the percentage of patients
safely treated for community-acquired pneumonia as out-
patients rather than requiring initial hospitalization [3].
However, up to 20% of patients fail outpatient treatment
and require subsequent hospitalization for pneumonia
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whether receiving prior outpatient antibiotic treatment
for pneumonia is associated with worse outcomes [5-7],
and the results are conflicting.
The study aim was to examine whether prior outpatient
antibiotic use is associated with increased 30-day mortal-
ity, after adjusting for potential confounders and severity
of illness at presentation, for patients hospitalized with
community-acquired pneumonia.
Methods
This a retrospective cohort study of patients hospitalized
with pneumonia at 2 academic tertiary care hospitals in
San Antonio, Texas. Both hospitals are teaching affiliates
of the University of Texas Health Science Center at San
Antonio. The Institutional Review Board of the University
Health Science Center at San Antonio approved the
research protocol with exempt status.
Study Sites/Inclusion and Exclusion Criteria
We identified all patients admitted to the study hospitals
between January 1, 1999 and December 1, 2002 with a
primary discharge diagnosis of pneumonia (ICD-9 codes
480.0–483.99 or 485–487.0) or secondary discharge diag-
nosis of pneumonia with a primary diagnosis of respira-
tory failure (518.81) or sepsis (038.xx). Subjects were
included if they were 1) greater than 18 years of age, 2)
had an admission diagnosis of pneumonia, and 3) had a
radiographically confirmed infiltrate or other finding con-
sistent with pneumonia on chest x-ray or CT obtained
within 24 hours of admission.
Exclusion criteria included 1) having been discharged
from an acute care facility within 14 days of admission, 2)
transfer after being admitted to another acute care hospi-
tal, 3) being a resident of a skilled nursing facility prior to
admission, and 4) being comfort measures only on this
admission. If a subject was admitted more than once dur-
ing the study period, only the first hospitalization was
abstracted.
Data Abstraction
Chart review data included: demographics, comorbid
conditions, physical examination findings, laboratory
data, and chest radiograph reports. In addition, data on
important processes of care measures for patients hospi-
talized with pneumonia were also abstracted: time to first
dose of antibiotics, collection of blood cultures prior to
antibiotic administration, and obtaining blood cultures
and oxygen saturation measurement within 24 hours of
presentation [8]. Antimicrobial therapy was considered
guideline-concordant if it agreed with either the 2000
Infectious Diseases Society of America or 2001 American
Thoracic Society guidelines [9,10], which are similar to
the recommendations from the 2007 joint guidelines
from these societies [11]. Information on all outpatient
medications that were either 1) reported as currently
being taken by the patient at presentation, or 2) listed in
the electronic medical record, were recorded. Patients
were defined as having prior antibiotic use if they had
received a prescription within the 30-days prior to hospi-
tal presentation.
Diagnostic criteria
Microbiologic data results were reviewed, and a microbio-
logic cause was assigned independently by two of the
investigators (MIR and EMM). The cause of pneumonia
was stratified as definitive or presumptive. The diagnosis
was considered definitive if one of the following condi-
tions were met: (1) positive blood cultures for bacterial or
fungal pathogens were obtained (in the absence of extra-
pulmonary source of infection); (2) pleural fluid cultures
yielded a bacterial pathogen; (3) endotracheal aspirates
with moderate or heavy growth of bacterial pathogens
were observed; (4) significant quantitative culture growth
from bronchoscopic respiratory samples were observed
(protected specimen brush cultures of at least 103 cfu/mL,
and in bronchoalveolar lavage of at least 104 cfu/mL). A
presumptive diagnosis was made if a qualitative valid spu-
tum sample yielded one or more predominant bacterial
pathogens. Definitive and presumptive causes were com-
bined for reporting purposes. When two or more micro-
biologic causes were present, the patient was considered
to have a polymicrobial infection. A patient was consid-
ered to have pneumonia of unknown cause if microbio-
logic studies were not performed or were inconclusive.
Risk Adjustment
The pneumonia severity index was used to assess severity
of illness at presentation [4]. The pneumonia severity
index is a validated prediction rule for 30-day mortality in
patients with community-acquired pneumonia. This rule
is based on three demographic characteristics, five comor-
bid illnesses, five physical examination findings, and
seven laboratory and radiographic findings from the time
of presentation. Patients are classified into five risk classes
with 30-day mortality ranging from 0.1% for class I to
27% for class V for patients enrolled in the PORT cohort
study [4].
Outcome
We used 30-day mortality as the outcome for this study.
Previous research has demonstrated that 30-day mortality
is primarily due to the pneumonia rather than other co-
existing co-morbid conditions.[12,13] Mortality was
assessed using information from the Texas Department of
Health and Department of Veteran Affairs clinical data-
base. Mortality status was assessed through December
2002.Page 2 of 6
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In a post-hoc power calculation, assuming an alpha of
0.05 and beta of 0.2, we were able to detect a 1.7× differ-
ence in mortality between the 2 groups.
Univariate statistics were used to test the association of
sociodemographic and clinical characteristics with all-
cause 30-day mortality. Categorical variables were ana-
lyzed using the Chi-square test and continuous variables
were analyzed using Student's t-test. A multivariable logis-
tic regression model was derived with 30-day mortality as
the dependent variable, and the pneumonia severity
index, process of care measures (initial antibiotics within
8 hours and whether antimicrobial therapy was guideline
concordant), and prior receipt of antibiotics within the
30-days prior to presentation as independent variables.
All analyses were performed using STATA version 9 (Stata
Corporation, College Station, Texas).
Results
Data was abstracted on 733 patients at the two hospitals.
The mean age was 59 years with a standard deviation of 16
years. The population was 78% male, 84% were admitted
through the emergency department, and 20% were admit-
ted to the intensive care unit (ICU) within the first 24
hours after admission. Mortality was 8.1% at 30-days and
12.1% at 90-days. By pneumonia severity index, 55%
were low risk (pneumonia severity index classes I-III),
33% were moderate risk (pneumonia severity index class
IV), and 12% were high risk (pneumonia severity index
class V).
In our cohort 17% (n = 128) of subjects received antibiot-
ics within 30-days of presentation. Unadjusted mortality
for those who had received prior antibiotics was 7.0% vs.
8.3% for those who had not (p = 0.6). There was also no
significant difference in length of stay (prior antibiotics-
6.9 days with a standard deviation (SD) of 8.7 vs. 7.8 days
and a SD of 16.7, p = 0.5) or rate of ICU admission (14%
vs. 20%, p = 0.1). Table 1 shows the demographic factors
and clinical characteristics for this population by prior
receipt of antibiotics. Table 2 shows the most commonly
received antibiotics prior to admission. These most com-
monly used antibiotics, in descending order, were levo-
floxacin (n = 31), amoxicillin (n = 17), azithromycin (n =
16), amoxicillin-clavulanate (n = 16), ciprofloxacin (n =
7), clarithromycin (n = 6), and erythromycin (n = 5).
Table 1: Subject demographic and clinical characteristics by receipt of antibiotics prior to admission*
Receipt of Antibiotics Prior to Admission
Variable Yes (n = 128) No (n = 605) p-value
Age, years (standard deviation) 58.2 (16.1) 59.7 (16.1) 0.3
Men 90 (70) 482 (86) 0.02
Admitted through emergency department 104 (81) 509 (89) 0.4
Admitted to intensive care within 24 hours 18 (14) 125 (20) 0.09
Preexisting Comorbid Conditions
Congestive heart failure 16 (13) 90 (15) 0.5
Chronic pulmonary disease 35 (27) 16 (22) 0.9
History of stroke 10 (8) 72 (12) 0.2
Chronic liver disease 3 (2) 34 (6) 0.1
History of malignancy 12 (9) 59 (10) 0.9
Renal insufficiency 13 (10) 58 (10) 0.8
History, Physical, Laboratory, and Radiographic Data
Altered mental status 12 (9) 56 (9) 0.9
Respiratory rate > 30 per minute 10 (8) 64 (11) 0.3
Systolic blood pressure < 90 mmHg 2 (2) 15 (2) 0.5
Heart rate > 125 per minute 12 (9) 86 (14) 0.1
Temperature < 95° or > 104° 0 (0) 20 (3) 0.04
Arterial pH < 7.35 5 (4) 4 (7) 0.2
Arterial oxygenation saturation < 90% 28 (22) 137 (23) 0.9
Hematocrit < 30% 9 (7) 56 (9) 0.4
Serum blood urea nitrogen > 30 mg/dL 27 (21) 120 (20) 0.8
Serum glucose > 250 mg/dL 14 (11) 60 (10) 0.7
Serum sodium < 130 meq/L 23 (18) 88 (15) 0.3
Pleural effusion on chest radiograph 27 (21) 147 (24) 0.4
Pneumonia Severity Index
Class I-III 74 (58) 330 (54)
Class IV 45 (35) 198 (33)
Class V 9 (7) 77 (13) 0.2
* Data are presented as number (%) or mean (standard deviation)Page 3 of 6
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organisms isolated in those with prior antibiotics with
15% versus 26% for those who did not receive antibiotics
prior to admission (p = 0.006). In addition, there was a
trend towards lower bacteremia in those who had received
outpatient antibiotics (9% vs. 16%, p = 0.07). Table 3
shows the most commonly isolated organisms. The only
isolated organisms that were significantly different
between groups were Streptococcus pneumoniae (2% in the
prior antibiotic group versus 10% in the non-use group)
and Haemophilus influenzae (0% vs 3% respectively). There
were no significant differences in resistance for either
Streptococcus pneumoniae (50% penicillin sensitive for
prior antibiotic users vs. 48% for non-users, p = 0.9) or
Staphylococcus aureus (50% methicillin sensitive for prior
antibiotic users vs. 82% for non users, p = 0.1).
In the multivariable analysis (Table 4), after adjusting for
potential confounders, prior use of antibiotics (odds ratio
0.98, 95% confidence interval 0.5–2.1) was not signifi-
cantly associated with 30-day mortality.
Discussion
We found that outpatient use of antibiotics prior to initial
hospital presentation was not significantly associated
with 30-day mortality for subjects hospitalized with pneu-
monia. In addition, we found no significant differences in
other important clinical variables or outcomes, such as
pneumonia severity index class, length of stay, and rates of
ICU admission, between those who did, and did not,
receive antibiotics prior to admission. These results are
reassuring that prior antibiotic therapy is not associated
with increased mortality and support the current meas-
ures to increase the number of patients with community-
acquired pneumonia that are treated as outpatients.
The prior literature regarding the association of prior anti-
biotic therapy and mortality is mixed. Our study supports
the findings of the recent study by van de Garde et al. [5]
of 1090 patients in the Netherlands who found that prior
antibiotic use was not associated with increased in-hospi-
tal mortality (OR 1.09, 95% CI 0.65–1.83). In addition,
Johnson et al[7] found in a study utilizing administrative
data of over 21000 subjects hospitalized with pneumonia
in Alberta, Canada that after risk adjustment receipt of any
antibiotic prior to admission was associated with
decreased mortality (OR 0.66, p < 0.0001). However, our
findings contrast with that of Meehan et al. [6,8], a nation-
wide study based on Medicare quality improvement data,
who found a small increase in mortality for those who
received antibiotics prior to admission (unadjusted mor-
tality 17.6% vs. 14.4%, multivariable model OR 1.32,
95% CI 1.28–1.37.) It is unclear however if this difference
was due to a direct impact of prior antibiotic therapy, or
was actually a marker for other, unmeasured, parts of the
medical care process, as was demonstrated by the protec-
tive association of blood cultures prior to antibiotics in
this same paper [8]. Also, our study may have had insuffi-
cient sample size to detect this small of a mortality differ-
ence. With our current sample we would have 67% power
to detect a similar difference in mortality.
Table 2: Antibiotics received within 30-days of hospital 













Table 3: Etiologic diagnosis by receipt of antibiotics prior to admission versus non-receipt*
Microorganisms Prior Antibiotic Use n = 128 N (%) No Prior Antibiotic Use n = 605 N (%) P-value
Streptococcus pneumoniae 2 (2) 58 (10) 0.003
Staphylococcus aureus 4 (3) 34 (6) 0.2
Pseudomonas aeruginosa 6 (5) 14 (2) 0.1
Haemophilus influenzae 0 (0) 19 (3) 0.04
Klebsiella pneumoniae 1 (1) 7 (1) 0.8
Escherichia coli 2 (1) 7 (1) 0.7
Proteus mirabilis 0 (0) 3 (1) 0.4
Miscellaneous ** 2 (2) 8 (1) 0.6
Polymicrobial 2 (2) 10 (2) 0.9
No pathogen isolated 109 (85) 445 (74) 0.006
* Percentages have been rounded and may not sum 100.
** Miscellaneous consists of Acinetobacter spp., Aspergillus spp., Haemophilus parainfluenzae, Enterococcus spp. and Streptococcus spp.Page 4 of 6
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therapy had significantly lower rates of bacterial identifi-
cation with lower rates of isolation of Streptococcus pneu-
moniae and Haemophilus influenzae. Interestingly we saw
no significant difference in rates of penicillin resistance
for Streptococcus pneumoniae or methicillin resistance Sta-
phylococcus aureus by prior antibiotic use. However, this
may be due to the small number of subjects who had spu-
tum cultures obtained (47%) or blood cultures obtained
prior to IV antibiotics (76%).
Although our study was retrospective and subject to the
recognized limitations of such studies, we carefully assem-
bled our cohort from complete patient discharge data to
avoid ascertainment bias. Additionally, during chart
abstraction we encountered a very small amount (<5%) of
missing data. Our sample was predominantly men due to
the inclusion of a VA hospital and it is possible, but
unlikely, that women may have differential responsive-
ness to antibiotic use as compared to men. Finally, we are
unable to ensure that all prior outpatient antibiotics were
prescribed for pneumonia and not another indication.
However, we do not believe that more than a very small
number of patients would have had another bacterial
infection (e.g., cellulitis, urinary tract infection) so closely
to the episode of pneumonia. This is also supported by
the fact that almost 1/3 of the antibiotics given were respi-
ratory fluoroquinolones, which during this time period,
and at these institutions, were the preferred outpatient
therapy for CAP patients with risk factors for drug resistant
Streptococcus pneumoniae. This supports our contention
that the vast majority of these antibiotics were used for
previously diagnosed pneumonia.
Conclusion
We found no association with prior outpatient use of anti-
biotics within 30-days of hospital presentation and mor-
tality for subjects hospitalized with community-acquired
pneumonia. In addition, we found no difference in other
markers for increased severity by prior antibiotic use
including length of stay, severity of illness at presentation,
and rate of ICU admission. Further research is needed to
determine if patients with community-acquired pneumo-
nia, who have had recent antibiotic use, are at risk for
multi-drug resistant organisms, which requires much
broader antimicrobial therapy.
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